Get the Stockscreener App
13.00
1.56%
0.20
Fulcrum Therapeutics Inc stock is traded at $13.00, with a volume of 1.59M.
It is up +1.56% in the last 24 hours and up +55.50% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$12.80
Open:
$12.8
24h Volume:
1.59M
Relative Volume:
1.34
Market Cap:
$703.54M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-8.2278
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
+46.07%
1M Performance:
+55.50%
6M Performance:
+91.74%
1Y Performance:
+222.58%
1-Day Range:
$12.58
$13.19
1-Week Range:
$12.07
$15.74
52-Week Range:
$2.315
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
13.00 | 692.72M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Hold at Wall Street Zen - MarketBeat
Firmware Signing Platform Market Size to Reach USD 6.29 Billion by 2033 | Report by SNS Insider - GlobeNewswire Inc.
Truist Securities Maintains Fulcrum Therapeutics (FULC) Buy Recommendation - Nasdaq
Ra Capital Management, L.P. Sells 4,175,139 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock - MarketBeat
Truist Securities raises Fulcrum Therapeutics stock price target on positive sickle cell data - Investing.com Canada
FULC: Truist Securities Raises Price Target for Fulcrum Therapeu - GuruFocus
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 5.7% After Insider Selling - MarketBeat
Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants - MSN
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock - MSN
Fulcrum shares jump 50% after early PIONEER trial data impress in sickle cell disease - MSN
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million By Investing.com - Investing.com Nigeria
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million - Investing.com
Fulcrum Therapeutics (NASDAQ:FULC) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Fulcrum Therapeutics (FULC) Expands Offering to $175M - GuruFocus
Fulcrum Therapeutics stock falls after pricing $175 million public offering By Investing.com - Investing.com Canada
Fulcrum Therapeutics prices $175 million public offering By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics Prices $175 Million Stock Offering - marketscreener.com
What is HC Wainwright's Forecast for FULC FY2028 Earnings? - MarketBeat
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Fulcrum Therapeutics announces pricing of upsized $175.0 million public offering of common stock and pre-funded warrants - marketscreener.com
Fulcrum Therapeutics Announces Pricing of $175 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Fulcrum Therapeutics (Nasdaq: FULC) sets $13.50 price for 11,851,853-share equity sale - Stock Titan
B of A Securities Maintains Fulcrum Therapeutics (FULC) Underperform Recommendation - Nasdaq
Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results - MSN
FULC: Analyst Rating Maintained by B of A Securities, Price Targ - GuruFocus
Bank of America Forecasts Strong Price Appreciation for Fulcrum Therapeutics (NASDAQ:FULC) Stock - MarketBeat
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 7.8% on Analyst Upgrade - MarketBeat
Fulcrum Therapeutics (FULC) Is Up 31.6% After $150M Stock Offering Following Positive Pociredir Data - Yahoo Finance
Fulcrum announces results from 20 mg dose cohort of Phase 1b PIONEER trial - MSN
Fulcrum Therapeutics dips after unveiling $150 million share sale - TradingView — Track All Markets
RBC Capital Maintains Fulcrum Therapeutics (FULC) Sector Perform Recommendation - Nasdaq
Fulcrum Therapeutics (FULC) Launches $150M Public Stock Offering - GuruFocus
Fulcrum stock drops after announcing $150 million public offering By Investing.com - Investing.com Australia
Fulcrum Therapeutics launches $150 million common stock offering - Investing.com
Fulcrum stock drops after announcing $150 million public offering - Investing.com
Fulcrum Therapeutics launches $150 million common stock offering By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Launches $150 Million Common Stock Offering - marketscreener.com
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock - The Manila Times
Fulcrum Therapeutics (Nasdaq: FULC) starts proposed $150.0M raise, plus $22.5M option - Stock Titan
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛
BofA Securities raises Fulcrum Therapeutics stock price target on SCD drug data - Investing.com Canada
Fulcrum Therapeutics’ Promising Surge: Analyzing Recent Progress - StocksToTrade
The growth track for Fulcrum Therapeutics Inc (FULC) has changed recently - Setenews
Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results - inkl
Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Piper Sandler Raises Price Target and Reiterates Overweight Rati - GuruFocus
Stifel raises Fulcrum Therapeutics stock price target to $25 on strong ASH data - Investing.com Canada
Fulcrum Therapeutics (NASDAQ:FULC) Sets New 12-Month High Following Analyst Upgrade - MarketBeat
Fulcrum Therapeutics jumps after trial data of blood disorder drug - TradingView — Track All Markets
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):